Trastuzumab deruxtecan (Tdx) is an antibody–drug conjugate of the humanised anti-HER2 Immunoglobulin (Ig) G1 and the topoisomerase I inhibitor, and it is currently the only HER2-targeted drug approved for NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.